keyword
https://read.qxmd.com/read/38629497/efficacy-and-safety-of-nemolizumab-and-topical-corticosteroids-for-prurigo-nodularis-results-from-a-randomised-double-blind-placebo-controlled-phase-ii-iii-clinical-study-in-patients-aged-%C3%A2-13-years
#21
JOURNAL ARTICLE
Hiroo Yokozeki, Hiroyuki Murota, Takayo Matsumura, Hiroshi Komazaki
BACKGROUND: Prurigo nodularis, a chronic inflammatory skin condition, adversely affects the quality of life of affected individuals. Current treatment options for prurigo nodularis in Japan are limited. OBJECTIVES: To evaluate the optimal dose, efficacy, and safety of long-term treatment with nemolizumab in patients with prurigo nodularis in Japan. METHODS: In a 16-week, double-blind, phase II/III study, patients aged ≥13 years with prurigo nodularis were randomly assigned (1:1:1) to nemolizumab 30 mg, 60 mg, or placebo groups, with concomitant topical corticosteroids, every 4 weeks...
April 17, 2024: British Journal of Dermatology
https://read.qxmd.com/read/38628635/a-case-of-persistent-pityriasis-rosea-successfully-treated-by-a-short-course-of-therapy-with-abrocitinib
#22
Hao Wu, Qing-Jie Ji, Yu-Yang Xu, Jian-Wei Zhu
Pityriasis rosea (PR) is a common inflammatory, erythematous and scaly skin condition that usually affects individuals aged from 20 to 40 years old. The disease often exhibits a self-limiting course up to 6-8 weeks. We report a 25-year-old female patient with a six-month history of red scaly rashes on the trunk and proximal limbs, accompanied by severe pruritus that has been remained ineffective conventional treatments. She was diagnosed as persistent pityriasis rosea. As abrocitinib has been proved to be effective for many inflammatory diseases, therefore in this case, we tried abrocitinib for the patient, and a good result had been achieved...
2024: Clinical, Cosmetic and Investigational Dermatology
https://read.qxmd.com/read/38628626/effects-of-abrocitinib-on-pruritus-and-eczema-symptoms-and-tolerance-in-patients-with-moderate%C3%A2-to%C3%A2-severe-atopic-dermatitis-in-randomized-double%C3%A2-blind-and-placebo%C3%A2-controlled-trials-a-systematic-review-and-a-meta%C3%A2-analysis
#23
JOURNAL ARTICLE
Xingxing Xie, Jie Zhang, Fujing Huang, Ling Fan
Abrocitinib is a highly selective Janus kinase 1 (JAK1) inhibitor that can block a multitude of inflammatory signaling pathways that underlie atopic dermatitis (AD). In addition, abrocitinib inhibits JAK1 signaling in sensory neurons to alleviate acute and chronic pruritus during AD. However, substantial variations in efficacy and safety risks remain due to variations in doses applied in clinical use. Therefore for the present study, differences in the efficacy and tolerability of 100 and 200 mg abrocitinib for treating pruritus and eczema symptoms in patients with moderate-to-severe AD were evaluated compared with placebo...
May 2024: Biomedical Reports
https://read.qxmd.com/read/38628046/therapeutic-textiles-a-promising-approach-for-human-skin-dysbiosis
#24
REVIEW
Cláudia Suellen Ferro de Oliveira, Freni Kekhasharú Tavaria
The close interaction between skin and clothing has become an attractive cornerstone for the development of therapeutic textiles able to alleviate skin disorders, namely those correlated to microbiota dysregulation. Skin microbiota imbalance is known in several skin diseases, including atopic dermatitis (AD), psoriasis, seborrheic dermatitis, rosacea, acne and hidradenitis suppurative (HS). Such microbiota dysregulation is usually correlated with inflammation, discomfort and pruritus. Although conventional treatments, that is, the administration of steroids and antibiotics, have shown some efficacy in treating and alleviating these symptoms, there are still disadvantages that need to be overcome...
April 2024: Experimental Dermatology
https://read.qxmd.com/read/38625661/ruxolitinib-cream-1-5-a-review-in-non-segmental-vitiligo
#25
REVIEW
Connie Kang
Topical ruxolitinib 1.5% cream (Opzelura® ), a Janus kinase (JAK) inhibitor, is the first treatment to be approved in several countries for use in patients aged ≥ 12 years with non-segmental vitiligo. In the identical phase III TRuE-V1 and TRuE-V2 trials, significantly more ruxolitinib cream recipients were able to achieve statistically significant and clinically meaningful facial and total body repigmentation, as well as reductions in vitiligo noticeability, compared with vehicle recipients...
April 16, 2024: Drugs
https://read.qxmd.com/read/38625007/us-guided-percutaneous-radiofrequency-ablation-for-secondary-hyperparathyroidism-long-term-outcomes-and-prognostic-factors
#26
JOURNAL ARTICLE
Wenwen Yue, Tingting Jiang, Zisheng Ai, Erya Deng, Huihui Chai, Xiaolong Li, Hongfeng He, Zhengxian Zhang, Ning Weng, Xiachuan Qin, Jing Fan, Xiaoqing Tang, Wei Heng, Yong Li, Liping Sun, Chengzhong Peng, Huixiong Xu
Background Although favorable outcomes have been reported with radiofrequency ablation (RFA) for secondary hyperparathyroidism (SHPT), the long-term efficacy remains insufficiently investigated. Purpose To evaluate the long-term efficacy and safety of US-guided percutaneous RFA in patients with SHPT undergoing dialysis and to identify possible predictors associated with treatment failure. Materials and Methods This retrospective study included consecutive patients with SHPT with at least one enlarged parathyroid gland accessible for RFA who were undergoing dialysis at seven tertiary centers from May 2013 to July 2022...
April 2024: Radiology
https://read.qxmd.com/read/38623662/cutaneous-larva-migrans
#27
H Bennani, M Raiteb, E El Mezouari, M Zyani, R Moutaj
BACKGROUND: Cutaneous larva migrans (CLM) is a helminthic infection found in tropical areas. It is commonly seen in patients in contact with soil contaminated by cat and dog hookworm larvae. CLM manifests as an erythematous, serpiginous, and pruritic cutaneous eruption. We present a case of a 27-year-old female with a serpiginous lesion on the plantar surface of the right foot. METHODS AND RESULTS: The patient was prescribed Albendazole at 400 mg twice a day for three days...
April 1, 2024: Clinical Laboratory
https://read.qxmd.com/read/38618041/case-report-a-rare-case-of-bilateral-middle-ear-tophaceous-gout
#28
Aybige Camurdan, Conrad Riemann, Frank Brasch, Ingo Todt
INTRODUCTION: Hypacusia can be caused by various etiologies; however, hearing loss attributed to gouty tophi remains a rare occurrence. This case report presents, for the first time, a bilateral gouty tophi causing hearing impairment. CASE PRESENTATION: This report describes a case study involving an 83-year-old Caucasian female patient who presented symptoms of hypacusia, pruritus, and a sensation of pressure in her right ear. A computed tomography scan revealed the presence of non-homogeneous calcified structures in both ears...
2024: Frontiers in Surgery
https://read.qxmd.com/read/38617599/a-phase-ib-ii-trial-of-capmatinib-plus-spartalizumab-vs-spartalizumab-alone-in-patients-with-pretreated-hepatocellular-carcinoma
#29
JOURNAL ARTICLE
Armando Santoro, Eric Assenat, Thomas Yau, Jean-Pierre Delord, Michela Maur, Jennifer Knox, Stephane Cattan, Kyung-Hun Lee, Gianluca Del Conte, Christoph Springfeld, Elisa Leo, Alexandros Xyrafas, Lauren Fairchild, Feby Mardjuadi, Stephen L Chan
BACKGROUND & AIMS: This phase Ib/II trial evaluated the safety and efficacy of capmatinib in combination with spartalizumab or spartalizumab alone in patients with advanced hepatocellular carcinoma (HCC). METHODS: Eligible patients who had progressed or were intolerant to sorafenib received escalating doses of capmatinib 200 mg, 300 mg, and 400 mg twice a day (bid) plus spartalizumab 300 mg every 3 weeks (q3w) in the phase Ib study. Once the recommended phase II dose (RP2D) was determined, the phase II study commenced with randomised 1:1 treatment with either capmatinib + spartalizumab (n = 32) or spartalizumab alone (n = 30)...
April 2024: JHEP reports: innovation in hepatology
https://read.qxmd.com/read/38615134/novel-topical-treatments-for-itch
#30
REVIEW
Rami H Mahmoud, Omar Mahmoud, Georgia Biazus Soares, Gil Yosipovitch
The experience of itch often poses a burden on patient quality of life and has the capacity to inflict significant suffering. Topical therapies are a mainstay of treatment for many cutaneous and systemic diseases and afford patients the opportunity to manage their conditions without many of the systemic side effects of non-topical therapies. We review a multitude of new topical medications targeting the skin, immune system, and neural receptors. The list includes Janus kinase inhibitors, tyrosine kinase inhibitors, phosphodiesterase inhibitors, transient receptor vanilloid inhibitors, topical cannabinoids, and topical acetaminophen...
April 13, 2024: Dermatology and Therapy
https://read.qxmd.com/read/38613839/sodium-bile-acid-co-transporter-inhibitors-currently-in-preclinical-or-early-clinical-development-for-the-treatment-of-primary-biliary-cholangitis
#31
REVIEW
Abhishek Gairola, Aaron Wetten, Jessica Dyson
INTRODUCTION: Pruritus is common and often undertreated in patients with primary biliary cholangitis (PBC). Existing treatments largely have an aging and low-quality evidence base, and studies included only small numbers of patients. More recent data that has added to our understanding of pruritus treatments has often come from clinical trials where itch was a secondary outcome measure in a trial designed primarily to assess disease modifying agents. This area represents an unmet clinical need in the management of PBC...
April 13, 2024: Expert Opinion on Investigational Drugs
https://read.qxmd.com/read/38613642/matching-adjusted-indirect-comparison-of-the-efficacy-at-week%C3%A2-32-of-tralokinumab-and-dupilumab-in-the-treatment-of-moderate-to-severe-atopic-dermatitis
#32
JOURNAL ARTICLE
Tiago Torres, Anne Sohrt Petersen, Ulla Ivens, Albert Bosch Vilaro, John Stinson, José Manuel Carrascosa
INTRODUCTION: Tralokinumab and dupilumab are biological agents licensed for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients who are candidates for systemic treatment. However, no head-to-head studies of their efficacy have been conducted. This study indirectly compared the efficacy of tralokinumab and dupilumab, both in combination with topical corticosteroids (TCS), at week 32. METHODS: An unanchored matching-adjusted indirect comparison was conducted using individual patient data (IPD) from the ECZTRA 3 tralokinumab trial and aggregate data from the LIBERTY AD CHRONOS dupilumab trial...
April 13, 2024: Dermatology and Therapy
https://read.qxmd.com/read/38612606/phytotherapy-of-vulvovaginal-candidiasis-a-narrative-review
#33
REVIEW
Natalia Picheta, Julia Piekarz, Oliwia Burdan, Małgorzata Satora, Rafał Tarkowski, Krzysztof Kułak
Vulvovaginal candidiasis (VVC) is a real gynecological problem among women of reproductive age from 15 to 49. A recent analysis showed that 75% of women will have an occurrence at least once per year, while 5% are observed to have recurrent vaginal mycosis-these patients may become unwell four or more times a year. This pathology is caused in 85-90% of cases by fungi of the Candida albicans species. It represents an intractable medical problem for female patients due to pain and pruritus. Due to the observation of an increasing number of strains resistant to standard preparations and an increase in the recurrence of this pathology when using local or oral preferential therapy, such as fluconazole, an analysis was launched to develop alternative methods of treating VVC using herbs such as dill, turmeric, and berberine...
March 28, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38607191/a-rare-case-of-benign-recurrent-intrahepatic-cholestasis-initially-diagnosed-in-middle-age
#34
JOURNAL ARTICLE
Fang Liu, Wei Li, Ming-Gang Zhang, Zhen-Mei Song, Xiao-di Wang, Xiu-Hong Wang, Shi-Yu Du
BACKGROUND: Repeated episodes of jaundice and pruritus are common in a group of autosomal recessive liver diseases known as benign recurrent intrahepatic cholestasis. Benign recurrent intrahepatic cholestasis (BRIC) is divided into two types, type 1 and type 2, and is caused by mutations in the ATP8B1 and ABCB11 genes. Here, we report a rare case of BRIC type 2 mutation. CASE PRESENTATION: A 45-year-old Chinese man had three frequent episodes of jaundice marked by extensive excoriation and severe pruritis, although he had no prior history of jaundice...
April 12, 2024: Alternative Therapies in Health and Medicine
https://read.qxmd.com/read/38607026/an-ox-tra-ordinary-tale-the-role-of-ox40-and-ox40l-in-atopic-dermatitis
#35
REVIEW
Kaviyon Sadrolashrafi, Lily Guo, Robin Kikuchi, Audrey Hao, Rebecca K Yamamoto, Hannah C Tolson, Sara N Bilimoria, Danielle K Yee, April W Armstrong
The transmembrane glycoprotein OX40 receptor (OX40) and its ligand, OX40L, are instrumental modulators of the adaptive immune response in humans. OX40 functions as a costimulatory molecule that promotes T cell activation, differentiation, and survival through ligation with OX40L. T cells play an integral role in the pathogenesis of several inflammatory skin conditions, including atopic dermatitis (AD). In particular, T helper 2 (TH 2) cells strongly contribute to AD pathogenesis via the production of cytokines associated with type 2 inflammation (e...
March 28, 2024: Cells
https://read.qxmd.com/read/38606161/skin-barrier-inflammatory-pathway-is-a-driver-of-the-psoriasis-atopic-dermatitis-transition
#36
REVIEW
Sitan Dong, Dongmei Li, Dongmei Shi
As chronic inflammatory conditions driven by immune dysregulation are influenced by genetics and environment factors, psoriasis and atopic dermatitis (AD) have traditionally been considered to be distinct diseases characterized by different T cell responses. Psoriasis, associated with type 17 helper T (Th17)-mediated inflammation, presents as well-defined scaly plaques with minimal pruritus. AD, primarily linked to Th2-mediated inflammation, presents with poorly defined erythema, dry skin, and intense itching...
2024: Frontiers in Medicine
https://read.qxmd.com/read/38600101/alternations-in-the-human-skin-gut-and-vaginal-microbiomes-in-perimenopausal-or-postmenopausal-vulvar-lichen-sclerosus
#37
JOURNAL ARTICLE
Xiaolei Ma, Guangdong Wen, Zheng Zhao, Lulu Lu, Tianying Li, Na Gao, Gangwen Han
Vulvar lichen sclerosus (VLS) is a chronic and progressive dermatologic condition that can cause physical dysfunction, disfigurement, and impaired quality of life. However, the etiology of VLS remains unknown. The vulvar skin, intestinal and vaginal microbiomes have been postulated to play important roles in the pathogenesis of this disease. The aim of this study was to compare the compositional characteristics of the vulvar skin, vagina, and gut microbiota between perimenopausal or postmenopausal VLS patients and healthy controls...
April 10, 2024: Scientific Reports
https://read.qxmd.com/read/38599660/defining-d-iraes-consensus-based-disease-definitions-for-the-diagnosis-of-dermatologic-adverse-events-from-immune-checkpoint-inhibitor-therapy
#38
JOURNAL ARTICLE
Steven T Chen, Yevgeniy R Semenov, Allireza Alloo, Daniel Q Bach, Allison Betof Warner, Amina Bougrine, Leeann Burton, Laura C Cappelli, Mariana Castells, Justine Cohen, Anna K Dewan, Riley Fadden, Lauren Guggina, Aparna Hegde, Victor Huang, Douglas B Johnson, Benjamin Kaffenberger, Daniela Kroshinsky, Shawn Kwatra, Bernice Kwong, Mario E Lacouture, Cecilia Larocca, Jonathan Leventhal, Alina Markova, Jon McDunn, Meghan J Mooradian, Jarushka Naidoo, Jennifer Choi, Vinod Nambudiri, Caroline A Nelson, Anisha B Patel, Julia Pimkina, Johnathan Rine, Krista M Rubin, Maxwell Sauder, Sheila Shaigany, Afreen Shariff, Ryan J Sullivan, Leyre Zubiri, Kerry L Reynolds, Nicole R LeBoeuf
With an increasing number of patients eligible for immune checkpoint inhibitors, the incidence of immune-related adverse events (irAEs) is on the rise. Dermatologic immune-related adverse events (D-irAEs) are the most common and earliest to manifest, often with important downstream consequences for the patient. Current guidelines lack clarity in terms of diagnostic criteria for D-irAEs. The goal of this project is to better define D-irAE for the purposes of identification, diagnosis, and future study of this important group of diseases...
April 10, 2024: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/38599621/icodextrin-induced-acute-generalized-exanthematous-pustulosis-in-a-patient-with-peritoneal-dialysis
#39
Chun-Hao Liu, Chien-Chou Chen, Chih-Chien Sung
Icodextrin has been widely prescribed for peritoneal dialysis (PD) patients with inadequate ultrafiltration, but icodextrin induced acute generalized exanthematous pustulosis (AGEP) has been not well recognized in clinical practice. We described a young-aged female with IgA nephropathy and end stage kidney disease under continuous automated peritoneal dialysis. She developed skin erythema with exfoliation over the groin 7th day after initiation of icodextrin based PD dialysate. Initially, her scaling skin lesion with pinhead-sized pustules affected the bilateral inguinal folds, and then it extended to general trunk accompanied by pruritus...
April 10, 2024: Nephrology
https://read.qxmd.com/read/38599160/evaluation-of-neuraxial-analgesia-on-outcomes-for-patients-undergoing-robot-assisted-abdominal-surgery
#40
REVIEW
P Greig, A Sotiriou, P Kailainathan, C Y M Carvalho, D N Onwochei, N Thurley, N Desai
STUDY OBJECTIVE: Following robot assisted abdominal surgery, the pain can be moderate in severity. Neuraxial analgesia may decrease the activity of the detrusor muscle, reduce the incidence of bladder spasm and provide effective somatic and visceral analgesia. In this systematic review, we assessed the role of neuraxial analgesia in robot assisted abdominal surgery. DESIGN: Systematic review. SETTINGS: Robot assisted abdominal surgery. PATIENTS: Adults...
April 9, 2024: Journal of Clinical Anesthesia
keyword
keyword
32335
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.